Cizzle Biotechnology completes evaluation programme with Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of using the Simple Western platform from ProteinSimple (a Bio-Techne brand) for high throughput detection of the CIZ1B cancer biomarker which may be useful in the detection of early-stage lung cancer.

The global lung cancer screening market is projected to grow from US$2.80 billion in 2021 to US$4.85 billion in 2028, representing a CAGR of 8.1% during the forecast period*. Furthermore, in 2021 the United States Preventive Services Task Force (USPSTF) updated its lung cancer screening guidelines** for annual screening with low-dose computed tomography (“LDCT”), reducing the lower limit of the screening age from 55 to 50 years and the minimum smoking history from 30 to 20 pack-years. Under the new guidelines, 14.5 million Americans may be eligible for annual screening with LDCT and other early-lung cancer screening tests which is estimated could save an additional 10,000-20,000 lives each year.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Cizzle Biotech

    More articles like this

    Cizzle Biotech

    Cizzle Biotechnology secures transaction with Conduit

    Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat